Jyoti Anand Kode
Advanced Centre for Treatment Research and Education in Cancer, ACTREC, Tata Memorial Centre, University of Poona, University of Mumbai
About
Dr. Jyoti Anand Kode holds expertise in the field of tumor immunology, stem cells and cancer. She recently superannuated from Advanced Centre of Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, India as a Principal Investigator and senior scientist at the Kode Lab, Tumor Immunology & Immunotherapy Group,. She has contributed significantly towards understanding role of immune cells, soluble plasma immune markers in cancer diagnostics, prognostics, stem cell immunobiology, transplant immunology and regenerative medicine. She has also been working on elucidating importance of formulations/ products/ nanocomposites derived from natural sources in developing cancer therapeutics. Her current research is focused on understanding innate immune inflammasome pathways in leukemia, lymphomas and oral cancers. She has been nominated by National Immunology Society (IIS) on General Assembly of IUIS (International Union of Immunological Societies) for term 2022-2025. She is a recipient of Dr L Sanghvi Oral Presentation Award through Mumbai Hematology Group and also recipient of Dr Jaju Award through Indian Association of Cancer Research. She has completed and also have many research projects ongoing funded by government agencies viz. CSIR, ICMR, Ministry of AYUSH, and Indian Co-operative Oncology Network (ICON). She is recipient of SERB Power (Promoting Opportunities for Women in Exploratory Research) program grant for Women. She has published her research in various international and national peer-reviewed journals and books. She has been an invited Member on Editorial Board of two international journals (WJSC, Cancer Biomarkers) and reviewer for more than 30 national/ international journals. She has received title as Outstanding Editorial Board member twice in year 2021 and 2023 from World Journal of Stem Cells, USA. She has been a part of few published and applied patents. Dr. Kode has mentored dissertation thesis work of many M.Sc./ M.Tech. /B.Tech and currently mentoring Ph.D. students in India. She is invited co-guide for students of MD (Ayurveda) at MUHS, Nashik, MD, PhD (Ayurveda) at NIA, Jaipur and PhD (Biotechnology) at Mumbai University. She has been on proposal review board of Ministry of AYUSH, Delhi; BRNS, Mumbai; SERB, Delhi, RGSTC, Government of Maharashtra and KSCSTE, Government of Kerala. She is invited thesis reviewer & viva examiner for DPU, Pune; IAR, Gujarat; Madras Univ, IIT-Madras, Chennai; NIIH, Mumbai University and BITS Pilani, Rajasthan. She has been actively engaged in conducting workshops and seminars for spreading knowledge to students/ teachers/ scientists/ clinicians and corporate members in the field of Tumor Immunology. She is a life member of many scientific societies (Immuno-Oncology Society of India; Society for Tissue Engineering and Regenerative Medicine (India) STERMI; Mumbai Immunology Group; Indian Association of Cancer Research; Mumbai Hematology Group; Indian Immunology Society and Secretary of Global Cancer Consortium South Asia Chapter (https://www.globalcancerconsortia.org/south-asia-chapter/). Dr. Kode has been actively engaged in organizing various educational seminars, symposia and scientific workshops for creating awareness in field of immunology & allied fields amongst college students/ teachers, academicians and corporate scientists. OrCID ID: http://orcid.org/0000-0001-6907-2449 ; Webpage: https://www.actrec.gov.in/dr-jyoti-anand-kode
Employment
-
Advanced Centre for Treatment Research and Education in Cancer Principal Investigator, Scientific Officer 'G'2020 - 2025
-
ACTREC, Tata Memorial Centre Principal Investigator, Scientific Officer1994 - 2025
Education
-
University of Poona M.Sc. Biotechnology1985 - 1987
-
University of Mumbai B.Sc. Microbiology1982 - 1985
Projects & Funding
Projects & funding information is unavailable.
Publications (91)
- A Phenstatin-based indole-chalcone hybrid as novel anti-inflammatory agent targeting the NLRP3 Inflammasome: Leads from computational and preclinical studies Save
- Preclinical efficacy and safety evaluation of a topical mesenchymal stem cell derived conditioned media gel for oral mucositis management Save
- Defining alteration in bone marrow mesenchymal stem cells (MSC) from acute myeloid leukemia and exploring cultured MSC-conditioned media as a novel anti-leukemia therapy agent Save
- Benzofluorene derivative exhibits antiproliferative effect against leukemia by tubulin polymerisation inhibition Save
- Generation and characterization of early stage oral cancer cell line of buccal mucosa of Indian origin Save
- Immune modulating therapy using UC-MSC-CM to inhibit tumor growth Save
- A traditional Cameroonian spice, Syzygium guineense curtails leukemia tumor growth through G2-M cell cycle arrest and predicted NLRP3 inflammasome pathway Save
- Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft model Save
- Improving In Vivo Tumor Accumulation and Efficacy of Platinum Antitumor Agents by Electronic Tuning of the Kinetic Lability Save
- Understanding dynamic interplay of 9a in regulating tumour-immune microenvironment in oral cancer: Cues from cutting-edge computational approaches (Poster 2201). Save